RxDoctor Payments Data

William Christian, MD

Cornea and External Diseases Specialist · Santa Monica, CANPI 1285825158

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $22,988 of the $32,686 with a category attached, or 70.3%. Johnson & Johnson Surgical Vision, Inc. accounts for 90.7% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $28,831 and has fallen 89.5% since, to $3,019 in 2025.

$32,686in general payments, 2019–2025

Across 38 payments — averaging $860.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Surgical Vision, Inc.$30K
  • Optos, Inc.$2K
  • Glaukos Corporation$1K
  • Carl Zeiss Meditec USA, Inc.$115
  • Novartis$91
  • AbbVie$69
  • plus $53 from 2 others

What the payments were for

  • Consulting fees$22,98870%
  • Speaking & faculty fees$5,50017%
  • Travel & lodging$2,7869%
  • Food & beverage$1,3234%
  • Gifts$390%
  • Entertainment$500%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,686 in reported general payments places this provider in the 80th percentile of 50 cornea and external diseases specialist providers in California.

See all cornea and external diseases specialist providers in California

Medicare billing

Part B allowed, 2024
$340,411
Medicare patients
612
Services billed
2,944

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost133$67,657
RestasisCyclosporine12$14,026
Brinzolamide39$10,088
Prednisolone Acetate152$7,626
Cyclosporine18$5,923
Brimonidine Tartrate50$5,839
AzoptBrinzolamide13$5,571
Bromfenac Sodium50$5,443
Travoprost24$3,976
Dorzolamide-TimololDorzolamide/Timolol/Pf12$3,096
Gatifloxacin65$2,768
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat147$2,761
Latanoprost228$2,131
Tobramycin-DexamethasoneTobramycin/Dexamethasone34$1,949
Dorzolamide Hcl61$1,312

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis$69$81,683145 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 50 cornea and external diseases specialist providers in California.

Other cornea and external diseases specialist in Santa Monica

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →